Drug intelligence / Profile preview

JZP505

Development stage: Phase 1
Lead developer: GW Communications
Modality: Small Molecules
Administration: Oral

Overview

JZP505 is an investigational oral cannabinoid being developed by Jazz Pharmaceuticals (originally initiated by GW Research, which was acquired by Jazz Pharmaceuticals in 2021). It is designed to target the endocannabinoid system. A Phase 1 first-in-human, randomized, double-blind, placebo-controlled study was completed in healthy adult volunteers to evaluate the safety, tolerability, food effect, and pharmacokinetics of single ascending doses (SAD) and multiple ascending doses (MAD) of oral JZP505.

Targets

CYP46A1 (Cholesterol 24-hydroxylase)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on JZP505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JZP505.